Advertisement
Advertisement
U.S. markets open in 6 hours 11 minutes
Advertisement
Advertisement
Advertisement
Advertisement

ERYTECH Pharma S.A. (ERYP.PA)

Paris - Paris Delayed Price. Currency in EUR
Add to watchlist
5.15-0.12 (-2.28%)
As of 9:04AM CEST. Market open.
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close5.27
Open5.19
Bid0.00 x 0
Ask0.00 x 0
Day's Range5.15 - 5.19
52 Week Range3.41 - 10.44
Volume13,746
Avg. Volume496,250
Market Cap143.793M
Beta (5Y Monthly)1.92
PE Ratio (TTM)N/A
EPS (TTM)-3.18
Earnings DateNov 15, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for ERYP.PA

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Monthly information related to total number of voting rights and shares composing the share capital – September 30, 2021.

      Monthly information related to total number of voting rights and shares composing the share capital – September 30, 2021. Article 223-16 of general regulation of French Autorité des Marchés FinanciersLyon – France Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP)Website : www.erytech.com DateTotal of shares composing the share capitalTotal of brut (1) voting rightsTotal of ne

    • GlobeNewswire

      ERYTECH Announces Maximum Tolerated Dose Declared in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer

      ERYTECH Announces Maximum Tolerated Dose Declared in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer No dose-limiting toxicity (DLT) reported in first two dose cohorts, leading to declaration of the maximum tolerated dose (MTD) at 100 U/kgEncouraging clinical activity observed in first patients Lyon (France) and Cambridge, MA (U.S.), October 4, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative the

    • GlobeNewswire

      ERYTECH to Participate in the HealthTech Innovation Days (HTID) by France Biotech

      ERYTECH to Participate in the HealthTech Innovation Days (HTID) by France Biotech Cambridge, MA (U.S.) and Lyon (France), September 28, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the company’s participation in one-on-one investor meetings at the HealthTech Innovation Days (HTID) by France Biotech being held in Paris and virtually on

    Advertisement
    Advertisement